Literature DB >> 10025576

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

A J Green1, R J Harvey, E J Thompson, M N Rossor.   

Abstract

Cerebrospinal fluid (CSF) concentrations of tau protein were measured using an enzyme-linked immunosorbent assay which measures both normal and hyperphosphorylated tau. Levels of CSF tau were measured in 17 patients with Alzheimer's disease and 23 patients with frontotemporal dementia, and were compared to age-matched healthy controls. The CSF tau concentration in control subjects was 198+/-49 pg/ml and no relationship was found between age and CSF tau concentrations in these subjects. CSF tau concentrations were significantly raised in patients with both Alzheimer's disease and frontotemporal dementia when compared to healthy controls (802+/-381 pg/ml, P<0.001; 612+/-382 pg/ml, P<0.05, respectively). In neither disease did CSF tau correlate with disease severity as assessed by the Mini Mental State Examination score (MMSE). This study shows that CSF tau is significantly raised in patients with frontotemporal dementia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10025576     DOI: 10.1016/s0304-3940(98)00904-5

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  33 in total

1.  Both total and phosphorylated tau are increased in Alzheimer's disease.

Authors:  M Sjögren; P Davidsson; M Tullberg; L Minthon; A Wallin; C Wikkelso; A K Granérus; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

Review 2.  Actin dynamics and cofilin-actin rods in alzheimer disease.

Authors:  James R Bamburg; Barbara W Bernstein
Journal:  Cytoskeleton (Hoboken)       Date:  2016-03-01

3.  CSF Tau proteins reduce misdiagnosis of sporadic Creutzfeldt-Jakob disease suspected cases with inconclusive 14-3-3 result.

Authors:  M J Leitão; I Baldeiras; M R Almeida; M H Ribeiro; A C Santos; M Ribeiro; J Tomás; S Rocha; I Santana; C R Oliveira
Journal:  J Neurol       Date:  2016-06-29       Impact factor: 4.849

Review 4.  CSF biomarkers for amyloid and tau pathology in Alzheimer's disease.

Authors:  Hanna Rosenmann
Journal:  J Mol Neurosci       Date:  2011-11-05       Impact factor: 3.444

5.  Reduced CSF carboxyterminally truncated Abeta peptides in frontotemporal lobe degenerations.

Authors:  M Bibl; B Mollenhauer; S Wolf; H Esselmann; P Lewczuk; J Kornhuber; J Wiltfang
Journal:  J Neural Transm (Vienna)       Date:  2007-01-25       Impact factor: 3.575

6.  CSF biomarkers in frontotemporal lobar degeneration with known pathology.

Authors:  H Bian; J C Van Swieten; S Leight; L Massimo; E Wood; M Forman; P Moore; I de Koning; C M Clark; S Rosso; J Trojanowski; V M-Y Lee; M Grossman
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

7.  Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications.

Authors:  M Sjögren; S Folkesson; K Blennow; E Tarkowski
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-08       Impact factor: 10.154

8.  Biological markers and Alzheimer disease: a canadian perspective.

Authors:  Hyman M Schipper
Journal:  Int J Alzheimers Dis       Date:  2010-08-08

9.  Genomic and Proteomic Biomarker Discovery in Neurological Disease.

Authors:  Rilee H Robeson; Andrew M Siegel; Travis Dunckley
Journal:  Biomark Insights       Date:  2008-02-09

10.  Alzheimer's Disease, Diagnosis and the Need for Biomarkers.

Authors:  Claudie Hooper; Simon Lovestone; Ricardo Sainz-Fuertes
Journal:  Biomark Insights       Date:  2008-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.